Empowering the immune system to recognize and eliminate tumors has tremendous potential to change the way cancer is treated and eventually cured.
At Fluidigm, we are focused on providing trusted research solutions to help you interrogate the tumor microenvironment, blood-based cancers and immune cell function with unprecedented resolution. Whether you seek to target new biomarkers and pathways or to optimize the effectiveness of checkpoint inhibitors, CAR T cells or cancer vaccines, Fluidigm can help you identify new insights to reach your next research breakthrough. Together we will transform the future of cancer care.
Visit Fluidigm at Booth 2417
Exhibit Dates & Hours:
- Sunday, April 2: 1:00–5:00 pm
- Monday, April 3: 9:00 am–5:00 pm
- Tuesday, April 4: 9:00 am–5:00 pm
- Wednesday, April 5: 9:00 am–12:00 pm
Deeply profile the tumor immune response from every angle.
Helios™, a CyTOF® System
Deeply profile immune cell subpopulations and identify signatures of checkpoint response using mass cytometry.
Reveal the molecular signatures of tumor immune response using a 170-target gene expression qPCR assay on the Biomark HD.
Achieve greater scalability and cost efficiency in NGS library preparation.
Find the missing link between T cell response and clonality with single-cell TCR sequencing on the C1 system.